Market Price

161.98 

-3.24 -2.0%

as of Jun 18 '21

52 Week Range:

133.65 173.65


Stock Analyzer Tutorials

S2O Stock Analyzer - General Info

General Info


type: video (mp4); length: 3:30

Demonstrates how to use Stock Analyzer, shows how to analyze a stock and explains in detail "General Info" section of the Stock Analyzer result page.

S2O Stock Analyzer - Financial Statements

Financial Statements


type: video (mp4); length: 5:10

Explains information presented in the Financial Statements section of the S2O Stock Analyzer: financial statements charts, absolute values and growth rates.

S2O Stock Analyzer - Growth Grade and Financial Ratios

Growth Grade and Financial Ratios


type: video (mp4); length: 5:09

Demonstrates how to use Growth Grade & Financial Ratios section; shows the difference between historical and year-over-year Growth Grade on the real life example.

S2O Stock Analyzer - Value Price

Value Price


type: video (mp4); length: 6:03

Demonstrates how to use Value Price (intrinsic value) and the Graham Number, MOS (margin of safety) and IRT - Investment Recovery Time; explains 3 different projection models used to compute value price - pessimistic, moderate and optimistic.

S2O Stock Analyzer - Price Charts

Price Charts


type: video (mp4); length: 8:34

Demonstrates basic rules of how to read a candlestick chart, long and short term moving averages, stochastic, MACD and relative strength (RS) charts. Explains how bull or bear market condition is computed.

General Info

Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; smoking cessation products under the NICORETTE brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides electrophysiology products to treat cardiovascular diseases and neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.

Financial Statements

The charts below show selected Annual and Quarterly Financial Data.

The purpose of these charts is to discover long and short term change dynamics. When numbers are growing year after year in the annual statements chart, the business become stronger and stronger and this is a good sign.

Quarterly Data Chart can be used to do a short term analysis. It makes sense to pay attention to the quarterly dynamics and do not wait for the next yearly statement. We should be alerted if we see that quarterly numbers are going down.

You can check "Annual Financial Statements" and "Quarterly Financial Statements" sections for exact numbers and growth rates.

Annual Statements

On a charts below the Line shows absolute values and the Bar chart shows Year-Over-Year Growth Rate for selected financial statement item. A consistent GROWTH is generally considered necessary to fund future growth from within a business.
NOTE: Growth Rate is not provided if either the latest period or the year-ago period contains a net loss. (source: WSJ Digest of Earnings)
TIP! move your mouse pointer over bar or a circle on any chart below to see details.

Financial Statements

Income Statement



 

Cash Flow Statement



 

Balance Sheet



 

Liquidity Ratios

Current Ratio


 

Current Ratio measures the ability to meet short term obligations. Generally accepted standard is 2 (current assets should be 2 times or 200% of current liabilities).

Quick Ratio


 

Measures immediate liquidity or the cash available to cover immediate liabilities. A safe margin would be at least 1 (100%).

Financial Leverage


 

Defined as total assets divided by total shareholders' equity. The higher the ratio, the more debt a company uses in its capital structure.

Profitability Ratios

ROA


 

Return on Assets (ROA) measures the income (profit) that is generated by the use of the assets of the business.

ROE


 

Return on Equity (ROE) is a measure of profitability that calculates how many dollars of profit a company generates with each dollar of shareholders equity. ROE is sometimes called "return on net worth."

ROIC


 

The Return on Invested Capital (ROIC) measure gives a sense of how well a company is using its money to generate returns. Some investors use this figure as a final evaluation to determine whether or not to invest in a company.

Annual Statements

Item Name Dec '12 Dec '13 Dec '14 Dec '15 Jan '16 Oct '16 Jan '17 Oct '17 Dec '18 Dec '19 Jan '21
Equity (BVPS) 23.33
24.75
27.52
25.86
26.75
27.58
24.27
22.11
24.49
growth rate 6.1% 11.2% -6.0% 1.7% 1.5% -12.0% -8.9% 10.8%
Earnings BIT 13,780.00
15,470.00
21,137.00
18,370.00
21,165.00
18,897.00
21,175.00
20,970.00
20,014.00
growth rate 12.3% 36.6% -6.8% 7.3% -10.7% 12.1% -1.0% -4.6%
Avg.PE 18.18
19.05
17.98
19.44
19.44
20.88
283.30
23.94
25.17
29.61
growth rate 4.8% -5.6% 8.1% 0.0% 3.6% 1,256.8% -91.6% 5.1% 17.6%
ROA 9.24
10.89
12.38
11.65
12.05
0.87
9.86
9.73
8.85
growth rate 17.9% 13.7% -5.9% 1.7% -73.1% 1,033.3% -1.3% -9.0%
ROE 17.81
19.92
22.70
21.87
23.37
1.99
25.51
25.36
23.97
growth rate 11.9% 14.0% -3.7% 3.4% -70.8% 1,181.9% -0.6% -5.5%
ROIC 14.22
16.39
18.47
17.55
17.86
1.69
16.90
17.01
15.93
growth rate 15.3% 12.7% -5.0% 0.9% -69.2% 900.0% 0.7% -6.4%
Cur. Ratio 1.90
2.20
2.36
2.17
2.47
1.41
1.47
1.26
1.21
growth rate 15.8% 7.3% -8.1% 6.7% -24.5% 4.3% -14.3% -4.0%
Quick Ratio 1.34
1.59
1.75
1.77
2.04
1.04
1.08
0.94
0.91
growth rate 18.7% 10.1% 1.1% 7.4% -28.6% 3.9% -13.0% -3.2%
Leverage 1.87
1.79
1.88
1.88
2.01
2.61
2.56
2.65
2.76
growth rate -4.3% 5.0% 0.0% 3.4% 14.0% -1.9% 3.5% 4.2%
Balance Sheet Dec '12 Dec '13 Dec '14 Dec '15 Jan '16 Oct '16 Jan '17 Oct '17 Dec '18 Dec '19 Jan '21
Acct.Receivable 14,448.00
15,320.00
10,985.00
10,734.00
11,699.00
13,490.00
14,098.00
14,481.00
13,576.00
growth rate 6.0% -28.3% -1.2% 4.4% 15.3% 4.5% 2.7% -6.3%
Acct.Payable 19,586.00
20,823.00
7,633.00
6,668.00
6,918.00
7,310.00
7,537.00
8,544.00
9,505.00
growth rate 6.3% -63.3% -6.5% 1.9% 5.7% 3.1% 13.4% 11.3%
Cur.Assets 46,116.00
56,407.00
55,744.00
60,210.00
65,032.00
43,088.00
46,033.00
45,274.00
51,237.00
growth rate 22.3% -1.2% 3.9% 3.9% -33.7% 6.8% -1.7% 13.2%
Total Assets 121,347.00
132,683.00
130,358.00
133,411.00
141,208.00
157,303.00
152,954.00
157,728.00
174,894.00
growth rate 9.3% -1.8% 1.2% 2.9% 11.4% -2.8% 3.1% 10.9%
Cash 14,911.00
20,927.00
14,523.00
13,732.00
18,972.00
17,824.00
18,107.00
17,305.00
13,985.00
growth rate 40.4% -30.6% -2.8% 17.5% -6.1% 1.6% -4.4% -19.2%
Inventory 7,495.00
7,878.00
8,184.00
8,053.00
8,144.00
8,765.00
8,599.00
9,020.00
9,344.00
growth rate 5.1% 3.9% -0.8% 0.6% 7.6% -1.9% 4.9% 3.6%
Cur.Liabilities 24,262.00
25,675.00
25,031.00
27,747.00
26,287.00
30,537.00
31,230.00
35,964.00
42,493.00
growth rate 5.8% -2.5% 5.3% -2.7% 16.2% 2.3% 15.2% 18.2%
Liabilities 56,521.00
58,630.00
60,606.00
62,261.00
70,790.00
97,143.00
93,202.00
98,257.00
111,616.00
growth rate 3.7% 3.4% 1.4% 6.6% 37.2% -4.1% 5.4% 13.6%
LT Debt 11,489.00
13,328.00
15,130.00
13,096.00
22,824.00
30,684.00
27,687.00
26,494.00
32,635.00
growth rate 16.0% 13.5% -7.0% 32.0% 34.4% -9.8% -4.3% 23.2%
Equity 64,826.00
74,053.00
69,752.00
71,150.00
70,418.00
60,160.00
59,752.00
59,471.00
63,278.00
growth rate 14.2% -5.8% 1.0% -0.5% -14.6% -0.7% -0.5% 6.4%
Common Shares 2,812.00
2,877.00
2,864.00
2,813.00
3,120.00
3,120.00
2,745.00
2,728.00
2,684.00
3,120.00
growth rate 2.3% -0.5% -1.8% 5.3% 0.0% -12.0% -0.6% -1.6% 16.2%
Cash Flow Statement Dec '12 Dec '13 Dec '14 Dec '15 Jan '16 Oct '16 Jan '17 Oct '17 Dec '18 Dec '19 Jan '21
Capital Expenditures 2,934.00
3,595.00
3,714.00
3,463.00
3,226.00
3,279.00
3,670.00
3,498.00
3,347.00
growth rate 22.5% 3.3% -3.4% -3.5% 1.6% 11.9% -4.7% -4.3%
Cash Dividends 6,614.00
7,286.00
7,768.00
8,173.00
8,621.00
8,943.00
9,494.00
9,917.00
10,481.00
growth rate 10.2% 6.6% 2.6% 2.7% 3.7% 6.2% 4.5% 5.7%
Cash From OA 15,396.00
17,414.00
18,710.00
19,569.00
18,767.00
21,056.00
22,201.00
23,416.00
23,536.00
growth rate 13.1% 7.4% 2.3% -2.1% 12.2% 5.4% 5.5% 0.5%
FCF per Share 4.43
4.65
5.08
5.30
4.79
6.71
6.76
7.31
6.85
growth rate 5.0% 9.3% 4.3% -4.9% 18.4% 0.8% 8.1% -6.3%
Sale Purchase of Stock -10,199.00
-889.00
1,543.00
1,005.00
1,189.00
1,062.00
growth rate 0.0% 100.0% -19.3% 8.8% -10.7%
FCF 12,462.00
13,819.00
14,757.00
15,816.00
16,106.00
15,541.00
15,541.00
17,777.00
18,531.00
19,918.00
20,189.00
growth rate 10.9% 6.8% 7.2% 1.8% -3.5% 0.0% 14.4% 4.2% 7.5% 1.4%
Income Statement Dec '12 Dec '13 Dec '14 Dec '15 Jan '16 Oct '16 Jan '17 Oct '17 Dec '18 Dec '19 Jan '21
Sales 67,224.00
71,312.00
74,331.00
70,074.00
71,890.00
76,450.00
81,581.00
82,059.00
82,584.00
growth rate 6.1% 4.2% -2.9% 1.3% 6.3% 6.7% 0.6% 0.6%
Op.Income 10,853.00
13,831.00
21,137.00
18,370.00
21,165.00
18,897.00
21,175.00
20,970.00
20,014.00
growth rate 27.4% 52.8% -6.8% 7.3% -10.7% 12.1% -1.0% -4.6%
IBT 13,775.00
15,471.00
20,563.00
19,196.00
19,803.00
17,673.00
17,999.00
17,328.00
16,497.00
growth rate 12.3% 32.9% -3.4% 1.6% -10.8% 1.8% -3.7% -4.8%
Net Income 10,853.00
13,831.00
16,323.00
15,409.00
16,540.00
1,300.00
15,297.00
15,119.00
14,714.00
growth rate 27.4% 18.0% -2.8% 3.6% -92.1% 1,076.7% -1.2% -2.7%
EPS 3.86
4.81
5.70
5.48
5.93
0.47
5.61
5.63
5.51
growth rate 24.6% 18.5% -3.9% 4.0% -71.9% 1,093.6% 0.4% -2.1%
Gross Profit 45,566.00
48,970.00
51,585.00
48,619.00
50,101.00
51,011.00
54,490.00
54,503.00
54,257.00
growth rate 7.5% 5.3% -2.9% 1.5% 1.8% 6.8% 0.0% -0.5%
R&D 7,665.00
8,183.00
8,494.00
9,046.00
9,143.00
10,594.00
10,775.00
11,355.00
12,159.00
growth rate 6.8% 3.8% 3.2% 0.5% 15.9% 1.7% 5.4% 7.1%

Quarterly Statements

Item Name Mar '20 Jun '20 Sep '20 Jan '21 Apr '21
Earnings BIT 5,934.00
4,168.00
5,966.00
3,946.00
6,844.00
growth rate -29.8% 43.1% -33.9% 73.4%
Balance Sheet Mar '20 Jun '20 Sep '20 Jan '21 Apr '21
Acct.Receivable 14,874.00
14,645.00
14,579.00
13,576.00
14,938.00
growth rate -1.5% -0.5% -6.9% 10.0%
Acct.Payable 7,411.00
6,765.00
7,044.00
9,505.00
8,503.00
growth rate -8.7% 4.1% 34.9% -10.5%
Cur.Assets 44,226.00
45,892.00
57,578.00
51,237.00
52,533.00
growth rate 3.8% 25.5% -11.0% 2.5%
Total Assets 155,017.00
158,380.00
170,693.00
174,894.00
172,557.00
growth rate 2.2% 7.8% 2.5% -1.3%
Cash 15,530.00
11,174.00
18,965.00
13,985.00
12,671.00
growth rate -28.1% 69.7% -26.3% -9.4%
Inventory 8,868.00
9,424.00
9,599.00
9,344.00
9,952.00
growth rate 6.3% 1.9% -2.7% 6.5%
Cur.Liabilities 33,689.00
36,772.00
38,847.00
42,493.00
40,932.00
growth rate 9.2% 5.6% 9.4% -3.7%
Liabilities 93,723.00
95,402.00
106,220.00
111,616.00
106,723.00
growth rate 1.8% 11.3% 5.1% -4.4%
LT Debt 25,393.00
25,062.00
32,680.00
32,635.00
30,263.00
growth rate -1.3% 30.4% -0.1% -7.3%
Equity 61,294.00
62,978.00
64,473.00
63,278.00
65,834.00
growth rate 2.8% 2.4% -1.9% 4.0%
Common Shares 3,120.00
3,120.00
3,120.00
3,120.00
3,120.00
growth rate 0.0% 0.0% 0.0% 0.0%
Cash Flow Statement Mar '20 Jun '20 Sep '20 Jan '21 Apr '21
Capital Expenditures 625.00
662.00
737.00
1,323.00
677.00
growth rate 5.9% 11.3% 79.5% -48.8%
Cash Dividends 2,505.00
2,659.00
2,659.00
2,658.00
2,659.00
growth rate 6.2% 0.0% 0.0% 0.0%
Cash From OA 3,358.00
3,452.00
8,383.00
8,343.00
4,074.00
growth rate 2.8% 142.8% -0.5% -51.2%
Sale Purchase of Stock
growth rate
FCF 2,733.00
2,790.00
7,646.00
7,020.00
3,397.00
growth rate 2.1% 174.1% -8.2% -51.6%
Income Statement Mar '20 Jun '20 Sep '20 Jan '21 Apr '21
Sales 20,691.00
18,336.00
21,082.00
22,475.00
22,321.00
growth rate -11.4% 15.0% 6.6% -0.7%
Op.Income 5,934.00
4,168.00
5,966.00
3,946.00
6,844.00
growth rate -29.8% 43.1% -33.9% 73.4%
IBT 6,509.00
3,940.00
4,401.00
1,647.00
7,429.00
growth rate -39.5% 11.7% -62.6% 351.1%
Net Income 5,796.00
3,626.00
3,554.00
1,738.00
6,197.00
growth rate -37.4% -2.0% -51.1% 256.6%
EPS
growth rate
Gross Profit 13,644.00
11,779.00
14,142.00
14,692.00
15,285.00
growth rate -13.7% 20.1% 3.9% 4.0%
R&D 2,580.00
2,707.00
2,840.00
4,032.00
3,178.00
growth rate 4.9% 4.9% 42.0% -21.2%

Growth Grade & Financial Ratios

All financial ratios below are calculated based on latest annual statements available and present the most up to date snapshot of a company finances.

Growth Grade

Historical Growth Grade:

E (28.88)

YOY Growth Grade:

E (23.42)

Click on buttons above for detailed yearly growth rates.

Market Ratios

Profitability Ratios

Liquidity Ratios

Efficiency Ratios

Value Price

PE and EPS

Historical Current Forward
PE 30.20 28.62 16.44
EPS / Growth 9.9% 5.66 7.5%

Value Price & Investment Recovery Time

Read more about Stock2Own value price in Stock Market: Fundamental Analysis.

Equity Growth Rate: 0.4%

Estimates Pessimistic Moderate Optimistic My Numbers
Rate of Return 15.0%
MOS Price % 50 %
Future EPS Growth 0.4% 5.9% 5.9%
Future PE 0.84 19.50 19.50
Future EPS 5.90 10.07 10.07
Value Price
MOS %
1.23
-99.2%
48.53
-70.0%
48.53
-70.0%
MOS Price 0.61 24.27 24.27
IRT 26.97 16.59 16.59

Graham Number:

NOTE: The Graham Number applies only to certain types of stocks in combination with a number of other criteria.

Read more about Graham Number in Stock Market: Fundamental Analysis.

Price Chart

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.

Risk / Reward Ratios

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.